• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Cytovance Biologics

    Alcami

    Baxter BioPharma Solutions

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    The Embedded CDMO

    Pfizer CentreOne’s JoyL Silva talks about the advantages of being parked inside Pfizer

    The Embedded CDMO
    Pfizer CentreOne’s general manager, JoyL Silva
    The Embedded CDMO
    Related CONTENT
    • Strata Oncology Unveils Strata PATH Trial
    • Reshaping the Pharmaceutical Supply Chain
    • Spark Therapeutics Appoints CTO
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    Tim Wright, Editor, Contract Pharma04.05.19
    Pfizer CentreOne is a global contract development and manufacturing organization (CDMO) embedded within Pfizer. It provides custom API synthesis, sterile injectable fill-finish and highly potent oral solid dose manufacturing capabilities. Pfizer CentreOne is also a leading supplier of steroid and hormone APIs and intermediates. For more than 40 years, Pfizer CentreOne has manufactured complex compounds for its biopharmaceutical partners, guiding their drugs from development through commercialization. Contract Pharma talked with Pfizer CentreOne’s general manager, JoyL Silva, about some of the benefits the embedded CDMO model offers, small molecule trends in general, as well Pfizer CentreOne’s plans and predictions for future growth.

    Contract Pharma (CP): How is Pfizer CentreOne ‘embedded’ in Pfizer?

    JoyL Silva (JS):
    Businesses operating as embedded contract development and manufacturing organizations (CDMOs) are self-contained organizations that work within larger companies. They use all the assets and resources of a larger company to manufacture compounds or drug products for their partners.

    As an embedded CDMO operating within Pfizer, we have access to Pfizer’s world-class facilities, technology and scientists to manufacture our partners’ products.

    CP: How does Pfizer CentreOne compete with standalone CDMOs? What advantages does being part of a major pharmaceutical company offer?

    JS:
    Put simply, being an embedded CDMO means that we can take advantage of Pfizer’s world leading capabilities. This means we have access to a global manufacturing network and some of the brightest scientific minds in the sector. We also follow stringent procedures to ensure the highest of quality standards, meaning we are a CDMO that our customers can trust to do the right thing.

    We can also take advantage of Pfizer’s ability to make significant investments in its facilities. For example, Pfizer has invested $1 billion in its pharmaceutical manufacturing plant in Kalamazoo, MI over the last decade, adding to the impressive portfolio of facilities and resources that Pfizer already has. 

    In addition, at Pfizer CentreOne we have the capabilities and scale to take products from Phase IIb to commercialization, which helps to simplify the supply chain for our customers.

    All our partners have a dedicated Pfizer CentreOne team made up of experts who can make the most of Pfizer’s resources, methods and capabilities.

    CP: Are different manufacturing sites used to manufacture Pfizer products and Pfizer CentreOne partner products?

    JS:
    No, one of the main advantages of partnering with Pfizer CentreOne is that our customers’ products are manufactured alongside Pfizer products, ensuring the highest quality standards and access to world leading technologies. This ultimately offers our customers peace of mind that their product is in safe hands.

    Pfizer CentreOne manufactures its customers’ products out of Pfizer’s facilities at multiple sites, including Kalamazoo, Rocky Mount, Zagreb in Croatia, Melbourne in Australia, Newbridge in Ireland and Nagoya in Japan.

    CP: Are clients concerned about handing over their IP to a Pfizer company?

    JS:
    We take confidentiality very seriously. Because we have a mixed-use model, where both Pfizer and Pfizer CentreOne partner products are manufactured at the same sites, we have strict policies, processes, tools and training in place to protect IP. The IP we protect includes both Pfizer’s and Pfizer CentreOne partners’ patents, copyrights, trademarks, scientific and technical knowledge, know-how and experience.

    Our commitment to confidentiality evidenced above means that we are seen as a safe pair of hands and we have earned the trust of our clients.

    CP: In which area is Pfizer CentreOne observing the greatest growth from clients, and in which geographies are these firms based?

    JS:
    At Pfizer CentreOne we are focused on providing specialty outsourced services to overcome complex manufacturing challenges and meet specific market demand. We are experiencing significant growth within our high potency oral solid dose (HP OSD) offering, particularly in the U.S. and Europe, as more potent compounds are being developed. High potency manufacturing requires special equipment, facilities and know-how, making outsourcing the preferred option for many companies developing these compounds. Pfizer continues to invest in its HP OSD facilities and our customers can take advantage of this. Our small molecule custom active pharmaceutical ingredient (API) offering is also in high demand as new and more challenging compounds enter the market.

    CP: What should we be expecting from Pfizer CentreOne over the next five years? Expansion in terms of facilities/headcount/manufacturing areas? Or increased specialization?

    JS:
    Our custom API offering is in high demand and we expect this side of our business to go from strength-to-strength over the next five years.

    Of course, we will continue to leverage Pfizer’s facilities and capabilities so that we can offer our partners reliable support from Phase IIb right through to commercialization.

    We are constantly evaluating the Pfizer network to see where there are opportunities for us to serve the market. Ultimately, we aim to address the development and manufacturing challenges faced by pharmaceutical companies today, as these challenges create the demand for outsourced capabilities and skills. Identifying these key areas and ensuring our offering is in line with market demand is our focus. In short, we must focus on delivering services that are of real value to pharmaceutical companies.

    CP: What do you predict for the future of small molecule development? Combination therapies? More complex molecules?

    JS:
    Firstly, small molecule products still make up a significant proportion of the market. While there is clear growth in biotech-based drugs, around 60%* of drugs in the current R&D pipeline are small molecule. This is reflected in the strong interest in our small molecule API capabilities and we expect this to continue.

    In terms of custom API development and manufacturing, there is a trend towards green chemistry and API synthesis using bio routes. More specifically, there is a rise in manufacturing using fermentation to shortcut long synthetic routes. At Pfizer CentreOne, we offer organic synthesis, fermentation and particle sizing capabilities all from our Kalamazoo site, making us uniquely positioned to deliver greener chemistry, while also improving efficiencies and reducing costs.

    CP: What other trends do you predict for 2019?

    JS:
    Another trend we expect to see continue into 2019 is pharmaceutical companies reducing their small molecule manufacturing footprints. This will fuel the rise in outsourcing and demand for CDMOs.

    Also, the high potency API market is experiencing significant growth, driven by demand for compounds to treat cancer, organ rejection and hormone products. In 2017 this segment of the market was valued at $16 billion and it is predicted to grow to $27 billion by 2023.**

    As the market grows, so does regulatory scrutiny and the need for clear guidance. High potency manufacturing requires effective containment, cleaning and validation in order to protect the health of both workers and patients. With no clear, harmonized standards from regulators at present, manufacturers are currently left to develop their own strategies and methodologies to ensure the safe handling of HP APIs and meet regulatory expectations. Currently, there is a move from the traditional regulatory model to a health-based model, which will influence the industry’s approach to containment strategies as we head into 2019. 

    *Pharma R&D Annual Review 2018, Pharmaprojects, Pharma Intelligence, Informa
    **Markets and Markets, April 2018
    Related Searches
    • training
    • High Potency
    • API
    • api synthesis
    Suggested For You
    Strata Oncology Unveils Strata PATH Trial Strata Oncology Unveils Strata PATH Trial
    Reshaping the Pharmaceutical Supply Chain Reshaping the Pharmaceutical Supply Chain
    Spark Therapeutics Appoints CTO Spark Therapeutics Appoints CTO
    Ashfield Engage, Popit Form Digital Monitoring Collaboration Ashfield Engage, Popit Form Digital Monitoring Collaboration
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    Pfizer Partners with Medicines Manufacturing Innovation Center Pfizer Partners with Medicines Manufacturing Innovation Center
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    Pfizer, BioNTech To Supply 200M More Vax Doses to EU Pfizer, BioNTech To Supply 200M More Vax Doses to EU
    Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine
    Pfizer Pfizer's 4Q Revenues up 12%
    Inside a Vaccine Trial Inside a Vaccine Trial
    Imcyse, Pfizer Enter Autoimmune Research Alliance Imcyse, Pfizer Enter Autoimmune Research Alliance
    Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine
    The State of Clinical Trial Technology The State of Clinical Trial Technology
    Pfizer, BioNTech Enter Vax Pact with COVAX  Pfizer, BioNTech Enter Vax Pact with COVAX

    Related Features

    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • APIs | Cytotoxics and High Potency Manufacturing
      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • APIs
      Small Molecule API CDMO: A Capital Intensive Business?

      Small Molecule API CDMO: A Capital Intensive Business?

      Exploring small molecule API market trends.
      Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers 03.01.21


    • Serialization
      Serialization: Level 5 Solution

      Serialization: Level 5 Solution

      Why a Level 5 solution is required for small pharma companies to fully harness serialization investment.
      Steve Wood, President & CEO, Covectra 03.01.21

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login